
Colossal Biosciences has secured a significant investment of $150 million in its Series B funding round, led by investors like Founders Fund and M12.
The company's business model is focused on developing and commercializing genetic technologies for de-extinction and genetic enhancement of existing species.
Colossal Biosciences has also partnered with Microsoft to utilize its Azure cloud platform for data analysis and storage, allowing for more efficient processing of genetic data.
This partnership is a key component of Colossal Biosciences' business model, enabling the company to scale its operations and accelerate its research.
Intriguing read: Quality Control and Genetic Algorithms
Colossal Biosciences Funding
Colossal Biosciences has received over $400 million in total funding from prominent investors, including TWG Global and Breyer Capital.
Their most recent funding round was a $200 million Series C investment in January 2025, which valued the company at $10.2 billion.
Colossal Biosciences has a significant scientific network, with over 170 scientists working across facilities in Dallas, Boston, and Melbourne.
Additional reading: Colossal Biosciences Stock
The company sponsors over 40 postdoctoral researchers globally and maintains a scientific advisory board of more than 95 experts.
Colossal Biosciences uses CRISPR technology to map and edit the genomes of extinct species, with the goal of resurrecting iconic creatures like the woolly mammoth, Tasmanian tiger, and dodo bird.
Their funding has allowed them to build a unique intersection of cutting-edge science, conservation, and commercial innovation.
De-Extinction Projects
Colossal Biosciences is leading the charge in de-extinction projects, and their flagship woolly mammoth project is a game-changer. They've made significant progress in resurrecting extinct species using innovative technologies.
Their woolly mammoth project has achieved critical milestones, including generating chromosome-scale reference genomes for multiple elephant species. This is a crucial step in understanding the genetic makeup of the woolly mammoth.
Colossal's team has also created the first de novo assembled mammoth genome from ancient DNA, a major breakthrough in the field. This achievement opens up new possibilities for de-extinction.
Expand your knowledge: Mammoth Brewing Company
Here are some of the key milestones in Colossal's woolly mammoth project:
- Generated chromosome-scale reference genomes for multiple elephant species.
- Created the first de novo assembled mammoth genome from ancient DNA.
- Established pluripotent stem cells for Asian elephants, a crucial step for in-vitro embryogenesis.
- Developed gene-editing protocols targeting cold-adaptation traits.
Colossal's work on the woolly mammoth project is not limited to this species. They're also working on reviving the Tasmanian tiger and dodo bird using sophisticated CRISPR technology.
Expand your knowledge: Change Battery
Business Model and Revenue
Colossal Biosciences has secured $435 million in funding with a $10.2 billion valuation, making it Texas's first decacorn. This impressive financial strength demonstrates both regional market validation and the company's impressive business approach.
The company's sophisticated revenue model encompasses multiple revenue streams, including technology licensing agreements, strategic government partnerships, and anticipated biodiversity credits. This diversified approach helps mitigate investment risks and creates a stable financial foundation.
Through licensing its advanced genetic engineering tools, Colossal can generate revenue from biotech companies and research institutions.
How Colossal Earns Money
Colossal Biosciences has secured $435 million in funding with a $10.2 billion valuation, demonstrating its impressive financial strength.
This substantial backing from sophisticated investors validates both their technology and business approach. The company's revenue model is sophisticated, encompassing technology licensing agreements, strategic government partnerships, and anticipated biodiversity credits.
Colossal earns money through licensing its advanced genetic engineering tools to biotech companies and research institutions. This stream of revenue is a significant contributor to the company's bottom line.
The company also generates revenue from government partnerships in conservation, creating additional revenue channels. Future plans include entering the biodiversity credits market once extinct species are successfully reintroduced.
Colossal's success in launching spin-off ventures demonstrates its business acumen. Form Bio, its computational biology platform, has secured $35 million in funding.
Another spin-off, Breaking, focuses on plastic degradation through engineered microbes and raised $10.5 million in seed funding. The company's diversified approach has established Colossal as both a pioneering force in de-extinction and a commercially viable enterprise in the biotechnology sector.
The company's recent $200 million funding round in January 2025 has enabled it to expand its operations and pursue new ventures.
Recommended read: Corporate Spin-off
Buying Stocks
Buying stocks can be a complex process, especially for those new to investing. Colossal Biosciences stock is only available via pre-IPO brokers and private market marketplaces.

To buy Colossal Biosciences stock, you'll need to work with a pre-IPO broker like TSG Capital Advisors. They can provide information on investing in Colossal Biosciences and help you learn about the stock price and latest news.
Investing in Colossal Biosciences can be done indirectly through pooled investment vehicles managed by TSG Invest fund managers. This option allows accredited investors to gain exposure to the company without directly purchasing the stock.
Investing and Financials
Colossal Biosciences has raised a total of $435 million across six funding rounds since its inception.
The company has demonstrated an impressive fundraising strategy, with multiple oversubscribed rounds and a valuation now reaching $10.2 billion. This scale and long-term vision are key to their ambitious projects.
Investors can buy Colossal Biosciences stock via a pre-IPO broker like TSG Capital Advisors or invest indirectly through pooled investment vehicles managed by TSG Invest fund managers.
Funding, Rounds, Investors
Colossal Biosciences Inc. has raised a total of $435 million across six funding rounds since its inception. This impressive trajectory demonstrates the company's ability to attract significant investment.
Their fundraising strategy emphasizes both the scale and long-term vision of their ambitious projects. This blend of grant support, venture backing, and strategic partnerships has enabled accelerated technology development, team expansion, and the scaling of conservation efforts.
Colossal Biosciences has had multiple oversubscribed rounds, showing strong demand for their innovative approach to biotechnology. This has contributed to their valuation reaching $10.2 billion.
Leading venture capital, technology, and industry names have invested in Colossal Biosciences. Their investor list includes prominent names that have helped shape the company's growth.
Additional reading: Cryptocoin Names
Is Publicly Traded
Colossal Biosciences is a privately held company, which means its shares are not available for public purchase on exchanges.
Investors who want to buy Colossal Biosciences stock can do so through a pre-IPO broker like TSG Capital Advisors.
You can also invest in Colossal Biosciences indirectly by using pooled investment vehicles, such as those managed by TSG Invest fund managers.
These investment options provide a way for investors to access the company's stock without it being publicly traded.
Key Players and Investors
Colossal Biosciences has a strong backing from prominent investors, including TWG Global, Breyer Capital, and notable figures like Peter Jackson and Paul Tudor Jones.
Tim Draper, a well-known venture capitalist, is also a key supporter of the company, contributing both capital and industry insight. He's known for his early investments in technology disruptors.
Breyer Capital, a global venture capital and private equity firm, is among the key investors in Colossal Biosciences, supplying expertise and growth capital for the company's long-term mission.
Here are some of the key investors in Colossal Biosciences:
- Tim Draper
- Breyer Capital
- Peter Jackson
- Paul Tudor Jones
- TWG Global
Key Highlights
Colossal Biosciences has achieved "decacorn" status with a valuation of $10.2 billion, a significant increase from its $1.45 billion valuation two years prior.
The company has raised over $400 million in total since its founding in 2021, with a recent $200 million Series C funding round contributing to this impressive total.
Colossal employs 170 scientists across three facilities in Dallas, Boston, and Melbourne, and sponsors over 40 postdoctoral researchers globally.

This substantial R&D infrastructure supports multiple concurrent projects in de-extinction, conservation, and biotechnology, making Colossal a leading player in the biotechnology landscape.
Here are some of the key investors backing Colossal Biosciences:
Colossal has secured partnerships with 48 conservation organizations worldwide, providing operational leverage and market validation for the company's ambitious projects.
Key Investors
Colossal Biosciences Inc. has attracted a strong lineup of investors, including venture capitalists, technology leaders, and industry experts.
Tim Draper, a prominent venture capitalist, is a key backer of the company, contributing both capital and industry insight.
Breyer Capital, a global venture capital and private equity firm, is another key investor, supplying expertise and growth capital for the company's long-term mission.
Colossal Biosciences Inc. has raised a total of $435 million across six funding rounds, with multiple oversubscribed rounds and a valuation now reaching $10.2 billion.
Their fundraising strategy emphasizes both the scale and long-term vision of their ambitious projects, with the support of grant funding, venture backing, and strategic partnerships.
For another approach, see: Genworth Long-term Care Settlement Options
Challenges and Uncertainties
Colossal Biosciences, a pioneer in de-extinction and synthetic biology, is a high-risk investment due to its competition from established biotech companies and genetic engineering startups.
Investing in Colossal Biosciences involves significant risks, particularly its early-stage status and current unprofitability. This warrants careful consideration, especially given its valuation anticipating significant future breakthroughs.
Regulatory challenges around genetic engineering and ethical considerations present additional risks that could result in financial and reputational impacts. These challenges are a major concern for investors.
The timeline for de-extinction projects is uncertain, spanning decades from DNA sequencing to successful embryo development. This extended development cycle impacts investment planning and ROI forecasting.
Each species presents unique biological challenges requiring tailored solutions, making it difficult to predict the outcome of a project.
Recommended read: What Risks Does Economic Growth Require
Future Outlook and Impact
Colossal Biosciences is poised to revolutionize the biotechnology industry with its innovative approach. The company's valuation of $10.2 billion following a $200 million Series C funding round is a testament to its potential.

Their diversified approach has led to the successful launch of valuable spin-offs, such as Form Bio, which has raised over $35 million. This demonstrates the company's ability to create value in multiple areas.
By 2028 and beyond, Colossal plans to complete its most ambitious projects, including de-extinction and artificial womb technology.
The Future Outlook
Colossal Biosciences has set its sights on ambitious de-extinction projects, with a goal of completing them by 2028 and beyond. The company is working towards bringing back extinct species through a combination of de-extinction, genetic engineering, and conservation biology.
Colossal has successfully launched valuable spin-offs, including Form Bio, a computational biology platform that has raised over $35 million. This demonstrates the company's ability to create value through innovation.
The company's artificial womb technology shows promise in fertility applications, in addition to its primary use in de-extinction. This technology has the potential to revolutionize reproductive medicine.
Colossal is pioneering a novel approach to conservation funding through biodiversity credits, similar to carbon credits. This innovative approach could provide a new way to support conservation efforts.
The company's strategic positioning at the intersection of biotechnology, conservation, and artificial intelligence presents distinct opportunities for growth and impact.
See what others are reading: A Corporation Is an Artificial Person Created by Law
World Problems, Solutions
Colossal's technology has caught the attention of the CIA's investment arm, In-Q-Tel, due to its potential to solve world problems.
Synthetic biology, the field Colossal operates in, is a global issue that requires a global solution, according to Ben, Colossal's representative.
The company's innovative approach has the potential to engineer life to secure disease, remove plastics, or clean up waterways, making it an attractive solution for governments worldwide.
Colossal's $225 million investment is being put to good use, employing 30 post-doc researchers and 110 employees worldwide, as well as supporting policy initiatives and collaborations with governments.
Colossal's goal is to bring new money into conservation, rather than diverting funds from existing conservation efforts, by targeting technology investors rather than traditional conservation groups.
The company is building a portfolio of conservation partnerships to help address the issue of extinction holistically and sustainably, including support for organizations protecting endangered elephants.
Broaden your view: CRST, the Transportation Solution
Frequently Asked Questions
Is Colossal Biosciences going to go public?
Colossal Biosciences has not yet filed for an IPO, but it may explore alternative paths to public trading. The company's future plans for public listing are not yet clear.
Featured Images: pexels.com


